Novel Sodium Channel Inhibitor From Leeches
Wang G, Long C, Liu W, Xu C, Zhang M, Li Q, Lu Q, Meng P, Li D, Rong M, Sun Z, Luo X, Lai R (2018) · Frontiers in Pharmacology · n=0
Study Profile
- Design
- molecular pharmacology and protein chemistry study of a novel peptide family (HSTX) isolated from leech salivary glands with functional electrophysiology characterization of voltage-gated sodium channel inhibition (Kunming Institute of Zoology, Chinese Academy of Sciences, China)
- Sample size (n)
- 0
- Intervention
- Identification, isolation, and structural characterization of 11 HSTX peptide family members from leech salivary glands; voltage-gated sodium channel inhibition assays for analgesic mechanism characterization
- Comparator
- Cross-peptide structure-activity comparison; selectivity profiling against multiple Nav channel isoforms
- Primary endpoint
- Identification of novel analgesic peptides; characterization of Nav1.8/Nav1.9 inhibitory potency; structural basis for analgesic action of leech-derived peptides
- Primary result
- Identified 11 HSTX peptides (22-25 amino acids, two intramolecular disulfide bridges, amidated C-terminus); HSTX-I exerts significant analgesic action by specifically inhibiting voltage-gated sodium channels Nav1.8 and Nav1.9 — key contributors to action-potential electrogenesis in nociceptive neurons; provides molecular explanation for the long-recognized clinical analgesic effects of leech therapy and identifies HSTX peptides as excellent candidates for new analgesic drug development
- Follow-up duration
- not applicable (peptide chemistry and electrophysiology mechanism study)
- PMID
- 29559913
Key Findings
- First molecular identification of a leech-derived peptide family with selective voltage-gated sodium channel inhibition
- HSTX-I specifically inhibits Nav1.8 and Nav1.9 - the principal nociceptor sodium channels and active targets for new analgesic development
- Eleven HSTX peptides characterized, 22-25 amino acids each with conserved disulfide architecture
- Provides a molecular explanation for the long-recognized analgesic effect of leech therapy across diverse pain indications
- Establishes leech salivary peptides as a promising scaffold for next-generation non-opioid analgesics
Limitations
- Mechanistic peptide-pharmacology study only - no clinical or in vivo analgesia data
- Selectivity profile beyond Nav1.8/Nav1.9 vs other Nav isoforms requires further characterization
- Pharmacokinetics, distribution, and safety of HSTX peptides untested
- Direct contribution of HSTX-I to whole-leech analgesia not quantified versus other leech analgesic compounds
- Single Chinese laboratory - independent replication not yet reported
Clinical Implications
Wang 2018 is a landmark mechanism paper for understanding leech-therapy analgesia. The discovery of HSTX peptides as selective Nav1.8/Nav1.9 inhibitors provides molecular justification for the broadly reported analgesic effects of leech therapy across pain conditions (knee OA, lateral epicondylitis, chronic low back pain, fibromyalgia, migraine). For ASH editorial purposes, the trial is essential mechanistic context for analgesic claims in clinical RCTs. For US clinicians, the trial does not change practice but supports the underlying mechanistic case that leech therapy produces a true molecular analgesic effect rather than purely placebo response. HSTX peptides may eventually emerge as a separate drug-development program independent of whole-leech therapy.